ClinicalTrials.Veeva

Menu

LeMaitre LifeSpan® ePTFE Vascular Graft Retrospective Registry

L

LeMaitre Vascular

Status

Completed

Conditions

Diseased or Occluded Blood Vessels
Arteriovenous Shunting for Blood Access

Treatments

Device: PVP
Device: AV Access

Study type

Observational

Funder types

Industry

Identifiers

NCT04620889
LFP-15-001

Details and patient eligibility

About

This is a post-market, single-arm, retrospective registry. The investigator or its representative will identify eligible patients through a medical record search.

Full description

This is a post-market, single-arm, retrospective registry. The investigator or its representative will identify eligible patients through a medical record search. Data will be captured retrospectively. Subjects will have been treated with the investigational device in the past and according to standard of care. Subjects will not be involved in any registry related procedures.

Enrollment

153 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject has undergone surgical treatment with the LifeSpan.
  • Surgical treatment was for bypass or reconstruction of diseased or occluded blood vessels (PVP group) or arteriovenous shunting for blood access (AV group).
  • For PVP group: Subject's surgical treatment was at minimum 3 years ago, and maximum 10 years ago, at time of enrollment.
  • For AV group: Subject's surgical treatment was at minimum 2 years ago, and maximum 10 years ago, at time of enrollment.

Exclusion criteria

  • None

Trial design

153 participants in 2 patient groups

PVP (peripheral vascular disease)
Description:
Bypass or reconstruction of diseased or occluded blood vessels
Treatment:
Device: PVP
AV Access (arteriovenous access)
Description:
Arteriovenous shunting for blood access and bypass.
Treatment:
Device: AV Access

Trial contacts and locations

1

Loading...

Central trial contact

Brian K Orrick

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems